Provider and household costs of Plasmodium vivax malaria episodes

a multicountry comparative analysis of primary trial data

Angela Devine, Ayodhia P. Pasaribu, Tedlla Teferi, Huong Thu Pham, Ghulam Rahim Awab, Febrina Contantia, Thuy Nhien Nguyen, Viet Thanh Ngo, Tinh Hien Tran, Asrat Hailu, Kim Gilchrist, Justin A. Green, Gavin Ckw Koh, Kamala Thriemer, Walter Rj Taylor, Nicholas Pj Day, Ric N. Price, Yoel Lubell

    Research output: Contribution to journalArticleResearchpeer-review

    Abstract

    Objective: To determine household and health-care provider costs associated with Plasmodium vivax infection across a range of endemic settings.

    Methods: We collected cost data alongside three multicentre clinical trials of P. vivax treatment in Afghanistan, Brazil, Colombia, Ethiopia, Indonesia, Philippines, Peru, Thailand and Viet Nam conducted between April 2014 to December 2017. We derived household costs from trial participant surveys administered at enrolment and again 2 weeks later to determine the costs of treatment and transportation, and the number of days that patients and their household caregivers were unable to undertake their usual activities. We determined costs of routine care by health-care providers by micro-costing the resources used to diagnose and treat P. vivax at the study sites.

    Findings: The mean total household costs ranged from 8.7 United States dollars (US$; standard deviation, SD: 4.3) in Afghanistan to US$ 254.7 (SD: 148.4) in Colombia. Across all countries, productivity losses were the largest household cost component, resulting in mean indirect costs ranging from US$ 5.3 (SD: 3.0) to US$ 220.8 (SD: 158.40). The range of health-care provider costs for routine care was US$ 3.6–6.6. The cost of administering a glucose-6-phosphate-dehydrogenase rapid diagnostic test, ranged from US$ 0.9 to 13.5, consistently lower than the costs of the widely-used fluorescent spot test (US$ 6.3 to 17.4).

    Conclusion: An episode of P. vivax malaria results in high costs to households. The costs of diagnosing and treating P. vivax are important inputs for future cost–effectiveness analyses to ensure optimal allocation of resources for malaria elimination.

    Original languageEnglish
    Pages (from-to)828-836
    Number of pages9
    JournalBulletin of the World Health Organization
    Volume97
    Issue number12
    DOIs
    Publication statusPublished - 1 Dec 2019

    Fingerprint

    Vivax Malaria
    Costs and Cost Analysis
    Plasmodium vivax
    Health Personnel
    Health Care Costs
    Afghanistan
    Colombia
    Malaria
    Peru
    Ethiopia
    Philippines
    Indonesia
    Resource Allocation
    Vietnam
    Glucosephosphate Dehydrogenase
    Thailand
    Routine Diagnostic Tests
    Caregivers
    Multicenter Studies
    Brazil

    Cite this

    Devine, Angela ; Pasaribu, Ayodhia P. ; Teferi, Tedlla ; Pham, Huong Thu ; Awab, Ghulam Rahim ; Contantia, Febrina ; Nguyen, Thuy Nhien ; Ngo, Viet Thanh ; Tran, Tinh Hien ; Hailu, Asrat ; Gilchrist, Kim ; Green, Justin A. ; Koh, Gavin Ckw ; Thriemer, Kamala ; Taylor, Walter Rj ; Day, Nicholas Pj ; Price, Ric N. ; Lubell, Yoel. / Provider and household costs of Plasmodium vivax malaria episodes : a multicountry comparative analysis of primary trial data. In: Bulletin of the World Health Organization. 2019 ; Vol. 97, No. 12. pp. 828-836.
    @article{9861d6f716ed4e51a1879c87c9dbd350,
    title = "Provider and household costs of Plasmodium vivax malaria episodes: a multicountry comparative analysis of primary trial data",
    abstract = "Objective: To determine household and health-care provider costs associated with Plasmodium vivax infection across a range of endemic settings.Methods: We collected cost data alongside three multicentre clinical trials of P. vivax treatment in Afghanistan, Brazil, Colombia, Ethiopia, Indonesia, Philippines, Peru, Thailand and Viet Nam conducted between April 2014 to December 2017. We derived household costs from trial participant surveys administered at enrolment and again 2 weeks later to determine the costs of treatment and transportation, and the number of days that patients and their household caregivers were unable to undertake their usual activities. We determined costs of routine care by health-care providers by micro-costing the resources used to diagnose and treat P. vivax at the study sites.Findings: The mean total household costs ranged from 8.7 United States dollars (US$; standard deviation, SD: 4.3) in Afghanistan to US$ 254.7 (SD: 148.4) in Colombia. Across all countries, productivity losses were the largest household cost component, resulting in mean indirect costs ranging from US$ 5.3 (SD: 3.0) to US$ 220.8 (SD: 158.40). The range of health-care provider costs for routine care was US$ 3.6–6.6. The cost of administering a glucose-6-phosphate-dehydrogenase rapid diagnostic test, ranged from US$ 0.9 to 13.5, consistently lower than the costs of the widely-used fluorescent spot test (US$ 6.3 to 17.4).Conclusion: An episode of P. vivax malaria results in high costs to households. The costs of diagnosing and treating P. vivax are important inputs for future cost–effectiveness analyses to ensure optimal allocation of resources for malaria elimination.",
    author = "Angela Devine and Pasaribu, {Ayodhia P.} and Tedlla Teferi and Pham, {Huong Thu} and Awab, {Ghulam Rahim} and Febrina Contantia and Nguyen, {Thuy Nhien} and Ngo, {Viet Thanh} and Tran, {Tinh Hien} and Asrat Hailu and Kim Gilchrist and Green, {Justin A.} and Koh, {Gavin Ckw} and Kamala Thriemer and Taylor, {Walter Rj} and Day, {Nicholas Pj} and Price, {Ric N.} and Yoel Lubell",
    year = "2019",
    month = "12",
    day = "1",
    doi = "10.2471/BLT.18.226688",
    language = "English",
    volume = "97",
    pages = "828--836",
    journal = "Bulletin of the World Health Organization",
    issn = "0042-9686",
    publisher = "World Health Organization",
    number = "12",

    }

    Devine, A, Pasaribu, AP, Teferi, T, Pham, HT, Awab, GR, Contantia, F, Nguyen, TN, Ngo, VT, Tran, TH, Hailu, A, Gilchrist, K, Green, JA, Koh, GC, Thriemer, K, Taylor, WR, Day, NP, Price, RN & Lubell, Y 2019, 'Provider and household costs of Plasmodium vivax malaria episodes: a multicountry comparative analysis of primary trial data', Bulletin of the World Health Organization, vol. 97, no. 12, pp. 828-836. https://doi.org/10.2471/BLT.18.226688

    Provider and household costs of Plasmodium vivax malaria episodes : a multicountry comparative analysis of primary trial data. / Devine, Angela; Pasaribu, Ayodhia P.; Teferi, Tedlla; Pham, Huong Thu; Awab, Ghulam Rahim; Contantia, Febrina; Nguyen, Thuy Nhien; Ngo, Viet Thanh; Tran, Tinh Hien; Hailu, Asrat; Gilchrist, Kim; Green, Justin A.; Koh, Gavin Ckw; Thriemer, Kamala; Taylor, Walter Rj; Day, Nicholas Pj; Price, Ric N.; Lubell, Yoel.

    In: Bulletin of the World Health Organization, Vol. 97, No. 12, 01.12.2019, p. 828-836.

    Research output: Contribution to journalArticleResearchpeer-review

    TY - JOUR

    T1 - Provider and household costs of Plasmodium vivax malaria episodes

    T2 - a multicountry comparative analysis of primary trial data

    AU - Devine, Angela

    AU - Pasaribu, Ayodhia P.

    AU - Teferi, Tedlla

    AU - Pham, Huong Thu

    AU - Awab, Ghulam Rahim

    AU - Contantia, Febrina

    AU - Nguyen, Thuy Nhien

    AU - Ngo, Viet Thanh

    AU - Tran, Tinh Hien

    AU - Hailu, Asrat

    AU - Gilchrist, Kim

    AU - Green, Justin A.

    AU - Koh, Gavin Ckw

    AU - Thriemer, Kamala

    AU - Taylor, Walter Rj

    AU - Day, Nicholas Pj

    AU - Price, Ric N.

    AU - Lubell, Yoel

    PY - 2019/12/1

    Y1 - 2019/12/1

    N2 - Objective: To determine household and health-care provider costs associated with Plasmodium vivax infection across a range of endemic settings.Methods: We collected cost data alongside three multicentre clinical trials of P. vivax treatment in Afghanistan, Brazil, Colombia, Ethiopia, Indonesia, Philippines, Peru, Thailand and Viet Nam conducted between April 2014 to December 2017. We derived household costs from trial participant surveys administered at enrolment and again 2 weeks later to determine the costs of treatment and transportation, and the number of days that patients and their household caregivers were unable to undertake their usual activities. We determined costs of routine care by health-care providers by micro-costing the resources used to diagnose and treat P. vivax at the study sites.Findings: The mean total household costs ranged from 8.7 United States dollars (US$; standard deviation, SD: 4.3) in Afghanistan to US$ 254.7 (SD: 148.4) in Colombia. Across all countries, productivity losses were the largest household cost component, resulting in mean indirect costs ranging from US$ 5.3 (SD: 3.0) to US$ 220.8 (SD: 158.40). The range of health-care provider costs for routine care was US$ 3.6–6.6. The cost of administering a glucose-6-phosphate-dehydrogenase rapid diagnostic test, ranged from US$ 0.9 to 13.5, consistently lower than the costs of the widely-used fluorescent spot test (US$ 6.3 to 17.4).Conclusion: An episode of P. vivax malaria results in high costs to households. The costs of diagnosing and treating P. vivax are important inputs for future cost–effectiveness analyses to ensure optimal allocation of resources for malaria elimination.

    AB - Objective: To determine household and health-care provider costs associated with Plasmodium vivax infection across a range of endemic settings.Methods: We collected cost data alongside three multicentre clinical trials of P. vivax treatment in Afghanistan, Brazil, Colombia, Ethiopia, Indonesia, Philippines, Peru, Thailand and Viet Nam conducted between April 2014 to December 2017. We derived household costs from trial participant surveys administered at enrolment and again 2 weeks later to determine the costs of treatment and transportation, and the number of days that patients and their household caregivers were unable to undertake their usual activities. We determined costs of routine care by health-care providers by micro-costing the resources used to diagnose and treat P. vivax at the study sites.Findings: The mean total household costs ranged from 8.7 United States dollars (US$; standard deviation, SD: 4.3) in Afghanistan to US$ 254.7 (SD: 148.4) in Colombia. Across all countries, productivity losses were the largest household cost component, resulting in mean indirect costs ranging from US$ 5.3 (SD: 3.0) to US$ 220.8 (SD: 158.40). The range of health-care provider costs for routine care was US$ 3.6–6.6. The cost of administering a glucose-6-phosphate-dehydrogenase rapid diagnostic test, ranged from US$ 0.9 to 13.5, consistently lower than the costs of the widely-used fluorescent spot test (US$ 6.3 to 17.4).Conclusion: An episode of P. vivax malaria results in high costs to households. The costs of diagnosing and treating P. vivax are important inputs for future cost–effectiveness analyses to ensure optimal allocation of resources for malaria elimination.

    UR - http://www.scopus.com/inward/record.url?scp=85076337419&partnerID=8YFLogxK

    U2 - 10.2471/BLT.18.226688

    DO - 10.2471/BLT.18.226688

    M3 - Article

    VL - 97

    SP - 828

    EP - 836

    JO - Bulletin of the World Health Organization

    JF - Bulletin of the World Health Organization

    SN - 0042-9686

    IS - 12

    ER -